Codon-Optimized rAAV Vectors for SURF1 Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective reagents for studying and delivering the SURF1 gene to treat SURF1 deficiency, Leigh Syndrome, and Charcot-Marie-Tooth disease 4K, which are severe neurological disorders associated with cytochrome c oxidase deficiency and lactic acidosis.
Innovation Solution
Development of recombinant adeno-associated viral (rAAV) vectors containing a codon-optimized SURF1 nucleic acid sequence, flanked by AAV inverted terminal repeats (ITRs) and a promoter, to deliver the SURF1 gene for therapeutic purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional gene delivery methods are used, then delivery capability is limited, but developing new viral vector systems increases complexity
Solution Approach 1:
The patent segments the gene delivery system into modular components: AAV2 ITR sequences for replication and packaging signals, heterologous promoter for transcriptional control, and the SURF1 cDNA transgene. This modular construction allows standardized assembly of functional gene delivery vectors while maintaining reliability through proven AAV-based delivery mechanisms.
2Quantity of substance
If wild-type SURF1 nucleic acid sequence is used, then expression level is insufficient, but codon optimization increases sequence divergence from native gene
Solution Approach 1:
The patent applies codon optimization to the SURF1 cDNA sequence, changing the nucleotide composition while preserving the amino acid sequence. This parameter change in the nucleic acid level (synonymous codon substitution) increases transcriptional efficiency and translational fidelity, achieving higher SURF1 protein expression levels without altering the functional protein product.
3Reliability
If high-dose gene therapy is administered, then therapeutic effect is improved, but risk of immune response and toxicity increases
Solution Approach 1:
The patent uses AAV2 viral vectors as intermediaries to deliver the SURF1 transgene. AAV vectors provide controlled, sustained gene expression and have favorable safety profiles with low immunogenicity compared to other viral vectors. This intermediary delivery system enables effective therapeutic dosing while minimizing immune responses and toxicity risks through its unique life cycle and tissue-specific transduction patterns.
Data Source
AI summary
The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to SURF1 loss and/or misfunction. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for a SURF1 polypeptide.